Information Provided By: 
Fly News Breaks for August 30, 2017
IMGN, JAZZ
Aug 30, 2017 | 07:20 EDT
Stifel analyst Annabel Samimy said the terms of Jazz Pharmaceuticals (JAZZ) and ImmunoGen's (IMGN) hematology-related antibody-drug conjugate collaboration are favorable for both parties and reflect respective risks associated with early-stage development as well as upside opportunity if development is successful. He keeps a Buy rating and $190 price target on Jazz shares.
News For JAZZ;IMGN From the Last 2 Days
There are no results for your query JAZZ;IMGN
